Theodore Pincus to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Theodore Pincus has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.305
-
RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol. Arthritis Care Res (Hoboken). 2011 Aug; 63(8):1142-9.
Score: 0.095
-
Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. J Rheumatol. 2008 Feb; 35(2):201-5.
Score: 0.073
-
Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for longterm observations in standard care to complement clinical trials. J Rheumatol. 2006 Dec; 33(12):2372-5.
Score: 0.069
-
An index of patient reported outcomes (PRO-Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. J Rheumatol. 2006 Nov; 33(11):2146-52.
Score: 0.068